

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.5	123.1	(53.0-242.7)	Male	4	4.0	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	6	3.3	179.9	(65.7-391.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	27	27.1	99.5	(65.6-144.8)	Female	2	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	10.0	139.5	(76.2-234.0)	Female	5	2.8	176.2	(56.8-411.1)
Female	9	9.0	100.1	(45.7-190.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.9	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	27.4	120.6	(83.0-169.4)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.2	nc	(nc-nc)	Female	9	5.5	162.7	(74.2-308.8)
Female	2	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	100	91.4	109.4	(89.0-133.0)
Male	1	1.5	nc	(nc-nc)	Female	88	86.1	102.2	(82.0-125.9)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	12.4	88.4	(44.1-158.1)					
Female	9	11.3	79.8	(36.4-151.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	19.2	124.9	(80.0-185.9)	Male	16	11.1	143.9	(82.2-233.6)
Female	7	7.7	90.4	(36.2-186.3)	Female	22	10.0	220.2	(137.9-333.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	10.1	69.5	(27.9-143.3)
Female	85	81.1	104.8	(83.7-129.6)	Female	16	10.0	160.3	(91.6-260.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.7	nc	(nc-nc)	Male	6	7.7	77.6	(28.4-169.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	35	29.1	120.1	(83.7-167.1)	Female	7	8.7	80.8	(32.4-166.5)
Female	32	31.0	103.2	(70.6-145.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.5	162.5	(74.1-308.4)
Male	9	5.0	178.9	(81.6-339.6)	Female	7	6.6	106.5	(42.7-219.4)
Female	2	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	91	76.8	118.5	(95.4-145.5)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.3	nc	(nc-nc)	Male	1	4.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	3.4	nc	(nc-nc)
Male	11	8.4	130.9	(65.2-234.2)	<u>Testis</u>				
Female	8	5.6	141.8	(61.1-279.4)	Male	1	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.3	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	9	8.5	106.3	(48.5-201.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	6.1	197.7	(102.0-345.3)	Female	15	16.7	89.8	(50.2-148.0)
Female	6	5.5	109.6	(40.0-238.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	281	259.0	108.5	(96.2-121.9)
Male	3	4.1	nc	(nc-nc)	Female	298	270.1	110.3	(98.2-123.6)
Female	1	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	35.9	69.6	(45.0-102.8)					
Female	46	36.3	126.8	(92.8-169.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

214

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	108	99.2	108.8	(89.3-131.4)	Male	61	53.6	113.9	(87.1-146.3)
Female	36	37.0	97.2	(68.1-134.6)	Female	82	45.5	180.1	(143.3-223.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	18.0	105.7	(63.6-165.1)	Male	20	14.9	134.3	(82.0-207.5)
Female	12	15.6	76.7	(39.6-134.1)	Female	7	11.8	59.5	(23.8-122.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	62	49.6	124.9	(95.8-160.1)
Female	452	366.6	123.3	(112.2-135.2)	Female	50	47.2	105.9	(78.6-139.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	16.0	56.2	(25.6-106.6)	Male	24	36.0	66.7	(42.8-99.3)
Female					Female	22	18.1	121.7	(76.2-184.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	136	147.2	92.4	(77.5-109.3)	Female	60	39.8	150.8	(115.1-194.2)
Female	113	148.4	76.2	(62.8-91.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	29	27.8	104.3	(69.9-149.8)
Male	17	24.7	68.7	(40.0-110.1)	Female	41	31.6	129.7	(93.1-175.9)
Female	7	7.2	96.8	(38.8-199.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	422	374.2	112.8	(102.3-124.1)
Male	7	7.2	97.7	(39.1-201.3)	<u>Stomach</u>				
Female	5	6.5	76.5	(24.7-178.6)	Male	24	25.2	95.2	(61.0-141.7)
<u>Kidney & Renal Pelvis</u>					Female	10	16.1	62.2	(29.8-114.5)
Male	46	40.2	114.5	(83.8-152.8)	<u>Testis</u>				
Female	34	26.4	129.0	(89.3-180.3)	Male	17	11.7	144.7	(84.2-231.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	16.0	62.7	(30.0-115.3)	Male	21	10.8	195.1	(120.7-298.2)
Female	5	4.5	109.9	(35.4-256.5)	Female	47	37.5	125.4	(92.1-166.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	30.5	85.1	(55.6-124.7)	Female	81	75.7	106.9	(84.9-132.9)
Female	33	26.1	126.4	(87.0-177.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1277	1282.5	99.6	(94.2-105.2)
Male	17	19.7	86.2	(50.2-138.0)	Female	1313	1254.7	104.6	(99.1-110.5)
Female	5	7.5	66.6	(21.5-155.5)					
<u>Lung and Bronchus</u>									
Male	123	181.4	67.8	(56.4-80.9)					
Female	118	172.5	68.4	(56.6-81.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

215

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.7	117.3	(53.5-222.6)	Male	9	6.0	149.0	(68.0-282.9)
Female	3	1.9	nc	(nc-nc)	Female	6	3.4	175.1	(63.9-381.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	29	26.9	107.9	(72.2-154.9)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	12.5	111.6	(61.0-187.3)	Female	3	2.7	nc	(nc-nc)
Female	4	7.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	2.4	293.8	(117.7-605.4)
Male	3	2.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	34.4	116.1	(83.0-158.2)
Male	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.1	240.5	(77.5-561.2)
<u>Kidney & Renal Pelvis</u>					Female	0	0.8	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Testis</u>				
Female	4	1.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	3.0	nc	(nc-nc)	Female	6	5.3	112.5	(41.1-244.8)
Female	4	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	120	120.0	100.0	(82.9-119.5)
Male	0	2.1	nc	(nc-nc)	Female	89	79.9	111.4	(89.5-137.1)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	15.1	118.9	(70.5-188.0)					
Female	11	9.5	116.4	(58.0-208.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

216

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	17.5	85.5	(47.8-141.0)	Male	6	9.2	65.6	(23.9-142.7)
Female	7	7.6	91.8	(36.8-189.2)	Female	2	8.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.1	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	8.6	151.6	(80.6-259.3)
Female	47	65.8	71.4	(52.5-95.0)	Female	10	9.4	106.5	(51.0-195.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	8	6.0	133.7	(57.6-263.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	25.7	101.1	(66.0-148.1)	Female	9	7.3	122.7	(56.0-232.9)
Female	34	30.5	111.5	(77.2-155.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	4.9	164.9	(71.0-324.9)
Male	5	4.3	116.7	(37.6-272.2)	Female	6	6.6	91.6	(33.4-199.3)
Female	3	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	83	65.3	127.0	(101.2-157.4)
Male	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.3	nc	(nc-nc)
Male	9	6.9	130.5	(59.5-247.7)	<u>Testis</u>				
Female	3	5.1	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.7	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	2	6.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.3	112.7	(41.2-245.3)	Female	15	13.7	109.8	(61.4-181.2)
Female	6	5.2	115.6	(42.2-251.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	253	223.7	113.1	(99.6-127.9)
Male	0	3.3	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	32.2	139.7	(101.9-187.0)					

Female 34 34.8 97.6 (67.6-136.4)

Female 217 239.4 90.7 (79.0-103.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

217

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	27.1	129.1	(89.9-179.6)	Male	17	15.5	110.0	(64.0-176.1)
Female	10	11.1	89.8	(43.0-165.1)	Female	22	13.6	161.7	(101.3-244.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.4	91.8	(29.6-214.2)	Male	6	4.1	145.3	(53.1-316.3)
Female	7	4.7	147.5	(59.1-304.0)	Female	4	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	18	14.2	126.8	(75.1-200.5)
Female	117	107.7	108.7	(89.9-130.3)	Female	12	14.2	84.3	(43.5-147.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.9	nc	(nc-nc)	Male	8	10.4	77.2	(33.2-152.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	40.7	98.4	(70.3-134.0)	Female	16	11.8	136.0	(77.7-220.9)
Female	57	45.7	124.8	(94.5-161.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	7.7	91.2	(36.5-187.8)
Male	11	6.9	160.3	(79.9-286.9)	Female	6	9.6	62.4	(22.8-135.8)
Female	4	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	105	102.1	102.8	(84.1-124.5)
Male	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.0	nc	(nc-nc)	Male	13	7.0	186.3	(99.1-318.6)
<u>Kidney & Renal Pelvis</u>					Female	4	5.1	nc	(nc-nc)
Male	7	11.4	61.4	(24.6-126.6)	<u>Testis</u>				
Female	6	7.8	77.1	(28.2-167.9)	Male	1	3.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.4	112.5	(36.3-262.5)	Male	3	3.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	8	11.3	70.8	(30.5-139.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.8	90.5	(39.0-178.4)	Female	25	21.7	115.1	(74.5-170.0)
Female	4	8.1	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	2	5.6	nc	(nc-nc)					
Female	2	2.3	nc	(nc-nc)					

Lung and Bronchus

Male	50	49.3	101.3	(75.2-133.6)
Female	44	50.2	87.7	(63.7-117.7)

All Sites / Types

Male	375	356.8	105.1	(94.7-116.3)
Female	382	373.9	102.2	(92.2-112.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

218

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.8	92.1	(57.0-140.9)	Male	19	14.4	132.2	(79.5-206.4)
Female	3	8.3	nc	(nc-nc)	Female	13	12.6	103.1	(54.8-176.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.2	190.7	(91.3-350.8)	Male	2	3.6	nc	(nc-nc)
Female	5	4.3	116.5	(37.5-271.8)	Female	6	2.6	226.5	(82.7-492.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	15	12.9	116.5	(65.2-192.2)
Female	114	95.9	118.9	(98.1-142.8)	Female	7	11.4	61.6	(24.7-126.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	4.8	nc	(nc-nc)	Male	6	9.8	61.5	(22.5-133.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	38	35.0	108.4	(76.7-148.8)	Female	7	10.2	69.0	(27.6-142.1)
Female	27	33.1	81.5	(53.7-118.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	6.6	150.8	(72.2-277.3)
Male	7	6.1	114.7	(45.9-236.3)	Female	4	7.0	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	83	92.7	89.5	(71.3-110.9)
Male	4	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.0	nc	(nc-nc)	Male	5	5.9	84.3	(27.2-196.8)
<u>Kidney & Renal Pelvis</u>					Female	2	3.5	nc	(nc-nc)
Male	11	10.5	104.3	(52.0-186.7)	<u>Testis</u>				
Female	3	6.5	nc	(nc-nc)	Male	7	4.4	157.8	(63.2-325.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.0	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	9	11.8	76.2	(34.8-144.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	7.9	nc	(nc-nc)					
Female	9	6.5	139.3	(63.6-264.5)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	4	5.2	nc	(nc-nc)					
Female	0	1.7	nc	(nc-nc)	Female	20	19.4	103.1	(62.9-159.2)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	64	43.1	148.4	(114.3-189.5)	Male	330	319.1	103.4	(92.5-115.2)
Female	40	40.2	99.5	(71.1-135.5)	Female	308	311.8	98.8	(88.1-110.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

219

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.1	158.3	(68.2-311.9)	Male	3	2.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	15	18.6	80.7	(45.1-133.1)	Female	2	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
					Female	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	7.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	7	7.1	99.0	(39.7-204.0)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	16	19.1	83.7	(47.8-136.0)
Female	0	0.3	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)

Female	2	1.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.0	nc	(nc-nc)	Female	5	3.8	130.9	(42.2-305.4)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male	50	66.5	75.2	(55.8-99.1)
Male	5	9.3	53.6	(17.3-125.1)	Female	51	62.5	81.5	(60.7-107.2)
Female	5	8.7	57.7	(18.6-134.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

220

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	13.0	76.7	(36.7-141.0)	Male	11	8.0	136.7	(68.1-244.6)
Female	1	4.5	nc	(nc-nc)	Female	10	6.5	153.8	(73.6-282.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
Female	62	52.0	119.1	(91.3-152.7)	Female	6	6.0	100.1	(36.6-218.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	6	5.7	106.0	(38.7-230.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	20.1	54.8	(27.3-98.0)	Female	8	5.5	146.6	(63.1-288.9)
Female	19	17.3	109.7	(66.0-171.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.8	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	Female	6	3.7	162.0	(59.2-352.7)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	58	55.7	104.1	(79.0-134.5)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.8	nc	(nc-nc)
Male	8	6.1	130.4	(56.2-257.0)	<u>Testis</u>				
Female	3	3.5	nc	(nc-nc)	Male	6	2.1	290.9	(106.2-633.1)
<u>Larynx</u>									
Male	1	2.4	nc	(nc-nc)					
Female	1	0.6	nc	(nc-nc)					

Leukemia

Male	4	4.4	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	2	3.0	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)

Lung and Bronchus

Male	20	25.3	79.1	(48.3-122.2)
Female	22	22.0	99.9	(62.6-151.3)

Thyroid

Male	2	1.9	nc	(nc-nc)
Female	6	5.9	100.9	(36.8-219.5)

Uteri Corpus and Uterus, NOS

Female	5	10.7	46.5	(15.0-108.6)
--------	---	------	------	--------------

All Sites / Types

Male	169	184.5	91.6	(78.3-106.5)
Female	180	166.6	108.1	(92.8-125.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

221

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	33	30.3	109.0	(75.0-153.1)	Male	18	16.9	106.3	(62.9-168.0)
Female	16	12.2	131.0	(74.8-212.7)	Female	15	15.5	96.7	(54.1-159.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	5.6	nc	(nc-nc)	Male	5	4.6	109.0	(35.1-254.5)
Female	2	5.2	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)	Male	14	15.5	90.1	(49.2-151.3)
Female	129	118.5	108.9	(90.9-129.4)	Female	14	15.8	88.5	(48.3-148.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	9	5.4	166.0	(75.7-315.1)	Male	14	11.4	123.0	(67.2-206.4)
Female	8	5.9	134.7	(58.0-265.4)	Ovary				
Colon / Rectum					Female	16	13.1	122.1	(69.8-198.3)
Male	43	45.3	94.9	(68.7-127.8)	Pancreas				
Female	47	50.2	93.6	(68.8-124.5)	Male	7	8.5	81.9	(32.8-168.7)
Esophagus					Female	9	10.5	85.3	(38.9-162.0)
Male	6	7.7	78.4	(28.6-170.7)	Prostate				
Female	3	2.4	nc	(nc-nc)	Male	89	114.3	77.8	(62.5-95.8)
Hodgkin Lymphoma					Stomach				
Male	3	2.4	nc	(nc-nc)	Male	6	7.8	77.4	(28.3-168.4)
Female	2	2.7	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
Kidney & Renal Pelvis					Testis				
Male	10	12.6	79.6	(38.1-146.3)					
Female	13	8.6	151.9	(80.8-259.7)					
Larynx									

Male	6	4.9	121.8	(44.5-265.1)
Female	1	1.4	nc	(nc-nc)

Leukemia

Male	7	9.4	74.4	(29.8-153.4)
Female	5	8.9	56.5	(18.2-131.8)

Liver and Intrahepatic Bile Ducts

Male	3	6.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)

Lung and Bronchus

Male	52	55.5	93.8	(70.0-123.0)
Female	56	55.3	101.3	(76.5-131.5)

Male	5	4.1	120.9	(39.0-282.1)
------	---	-----	-------	--------------

Thyroid

Male	1	3.5	nc	(nc-nc)
Female	6	13.3	45.1	(16.5-98.3)

Uteri Corpus and Uterus, NOS

Female	20	24.0	83.3	(50.8-128.6)
--------	----	------	------	--------------

All Sites / Types

Male	353	395.8	89.2	(80.1-99.0)
Female	403	414.0	97.4	(88.1-107.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	12.2	49.2	(18.0-107.1)	Male	3	7.7	nc	(nc-nc)
Female	0	4.2	nc	(nc-nc)	Female	7	6.5	107.9	(43.2-222.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
Female	48	51.2	93.8	(69.2-124.4)	Female	3	5.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.5	nc	(nc-nc)	Male	8	5.5	146.8	(63.2-289.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	18.9	63.6	(32.8-111.1)	Female	5	5.3	93.7	(30.2-218.8)
Female	18	16.5	109.1	(64.6-172.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.6	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	52.2	105.4	(79.4-137.2)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>									
Male	6	5.8	102.8	(37.5-223.8)					

Female	4	3.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	2.2	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male	1	1.8	nc	(nc-nc)
Male	1	4.2	nc	(nc-nc)	Female	8	6.1	131.6	(56.7-259.4)
Female	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female	10	10.4	96.1	(46.0-176.7)
Male	1	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.9	nc	(nc-nc)	Male	142	174.2	81.5	(68.6-96.1)
<u>Lung and Bronchus</u>					Female	157	161.8	97.1	(82.5-113.5)
Male	18	23.6	76.2	(45.1-120.4)					
Female	22	20.9	105.4	(66.0-159.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

223

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	13.6	95.4	(50.7-163.2)	Male	5	7.7	64.9	(20.9-151.6)
Female	2	5.7	nc	(nc-nc)	Female	4	6.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
Female	42	53.4	78.6	(56.6-106.2)	Female	9	7.2	125.0	(57.0-237.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	5	5.1	98.2	(31.6-229.2)
<u>Colon / Rectum</u>					Female	0	2.7	nc	(nc-nc)
Male	24	20.4	117.8	(75.5-175.3)	<u>Ovary</u>				
Female	31	23.2	133.4	(90.6-189.4)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.4	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	5	4.9	102.2	(32.9-238.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	49	50.6	96.8	(71.6-127.9)
Female	0	1.0	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	9	5.7	158.9	(72.5-301.7)
Female	5	3.9	128.0	(41.2-298.7)

Larynx

Male	2	2.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)

Leukemia

Male	3	4.4	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	2	2.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)

Lung and Bronchus

Male	17	24.8	68.6	(40.0-109.9)
Female	19	25.3	75.0	(45.1-117.1)

Stomach

Male	6	3.5	170.8	(62.4-371.7)
Female	1	2.6	nc	(nc-nc)

Testis

Male	1	2.0	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	2	1.6	nc	(nc-nc)
Female	3	5.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	15	10.8	138.8	(77.6-229.0)
--------	----	------	-------	--------------

All Sites / Types

Male	157	178.0	88.2	(74.9-103.1)
Female	162	188.0	86.2	(73.4-100.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

224

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	13	12.9	100.8	(53.6-172.4)	Female	4	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.6	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	<u>Ovary</u>				
Female	5	4.8	104.3	(33.6-243.5)	Female	3	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	2	0.3	nc	(nc-nc)	Male	10	13.7	73.2	(35.0-134.6)
Female	0	0.2	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	5	2.6	189.3	(61.0-441.8)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	6.4	nc	(nc-nc)	Male	32	45.7	70.1	(47.9-98.9)
Female	4	5.8	nc	(nc-nc)	Female	48	42.7	112.4	(82.9-149.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

225

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.7	86.7	(43.2-155.1)	Male	7	8.5	82.4	(33.0-169.8)
Female	4	4.8	nc	(nc-nc)	Female	12	7.7	154.9	(79.9-270.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.2	186.1	(67.9-405.0)	Male	1	2.0	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.5	nc	(nc-nc)
Female	36	57.1	63.1	(44.2-87.3)	Female	10	6.7	148.7	(71.2-273.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
					Female	5	2.7	187.6	(60.5-437.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	19.8	126.0	(81.5-186.0)	Female	4	6.1	nc	(nc-nc)
Female	10	19.3	51.7	(24.8-95.1)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.5	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)

Female	1	0.9	nc	(nc-nc)	Female	6	4.0	148.3	(54.1-322.7)
Hodgkin Lymphoma					Prostate				
Male	0	1.5	nc	(nc-nc)	Male	45	53.3	84.4	(61.5-112.9)
Female	2	1.4	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	4	3.3	nc	(nc-nc)
Male	8	6.2	129.3	(55.7-254.8)	Female	4	2.1	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Testis				
Larynx					Male	6	2.9	207.2	(75.7-451.1)
Male	2	2.3	nc	(nc-nc)	Thyroid				
Female	3	0.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Leukemia					Female	8	7.5	106.0	(45.6-208.9)
Male	5	4.7	106.5	(34.3-248.5)	Uteri Corpus and Uterus, NOS				
Female	2	3.9	nc	(nc-nc)	Female	10	11.5	86.9	(41.6-159.7)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	2	3.0	nc	(nc-nc)	Male	180	183.8	97.9	(84.2-113.3)
Female	1	1.0	nc	(nc-nc)	Female	166	185.2	89.6	(76.5-104.4)
Lung and Bronchus									
Male	29	24.2	119.8	(80.2-172.0)					
Female	23	23.0	100.0	(63.4-150.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

226

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	16	11.2	142.6	(81.4-231.6)	Male	9	6.5	138.5	(63.2-262.9)
Female	3	4.0	nc	(nc-nc)	Female	12	5.2	232.2	(119.8-405.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	8	5.9	135.7	(58.4-267.4)
Female	47	43.0	109.2	(80.2-145.2)	Female	5	5.2	96.9	(31.2-226.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.9	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Colon / Rectum					Female	1	2.0	nc	(nc-nc)
Male	14	17.1	81.8	(44.7-137.2)	Ovary				
Female	13	16.1	81.0	(43.1-138.5)	Female	4	4.6	nc	(nc-nc)

Esophagus

Male	5	3.0	166.8	(53.7-389.2)
Female	1	0.8	nc	(nc-nc)

Hodgkin Lymphoma

Male	2	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)

Kidney & Renal Pelvis

Male	2	5.0	nc	(nc-nc)
Female	6	3.0	203.0	(74.1-441.9)

Larynx

Male	2	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Leukemia

Male	1	3.6	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	4	2.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)

Lung and Bronchus

Male	19	21.2	89.4	(53.8-139.6)
Female	11	18.8	58.6	(29.2-104.9)

Pancreas

Male	1	3.3	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)

Prostate

Male	43	46.8	91.9	(66.5-123.7)
------	----	------	------	--------------

Stomach

Male	2	2.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)

Testis

Male	0	1.3	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	5	1.4	359.4	(115.8-838.7)
Female	6	4.4	137.5	(50.2-299.2)

Uteri Corpus and Uterus, NOS

Female	11	9.0	122.1	(60.8-218.4)
--------	----	-----	-------	--------------

All Sites / Types

Male	152	154.1	98.6	(83.6-115.6)
Female	142	141.6	100.3	(84.5-118.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

227

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	35.8	83.8	(56.5-119.6)	Male	25	19.0	131.9	(85.3-194.7)
Female	11	14.3	77.1	(38.4-137.9)	Female	20	16.3	122.8	(75.0-189.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	6.3	207.1	(110.2-354.2)	Male	8	5.3	150.4	(64.7-296.3)
Female	10	5.6	178.0	(85.2-327.3)	Female	5	4.5	111.1	(35.8-259.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	12	17.6	68.0	(35.1-118.9)
Female	103	130.0	79.3	(64.7-96.1)	Female	16	17.8	90.0	(51.4-146.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.6	nc	(nc-nc)	Male	6	12.3	48.8	(17.8-106.2)
					Female	7	6.6	106.0	(42.5-218.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				

Male	64	52.7	121.5	(93.6-155.2)					
Female	55	56.8	96.9	(73.0-126.1)					
<u>Esophagus</u>									
Male	10	8.8	113.8	(54.5-209.2)					
Female	4	2.8	nc	(nc-nc)					
<u>Hodgkin Lymphoma</u>									
Male	3	2.5	nc	(nc-nc)					
Female	1	2.2	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>									
Male	9	14.2	63.4	(28.9-120.4)					
Female	11	9.8	112.7	(56.2-201.7)					
<u>Larynx</u>									
Male	12	5.6	213.3	(110.1-372.6)					
Female	1	1.7	nc	(nc-nc)					
<u>Leukemia</u>									
Male	13	10.9	119.1	(63.4-203.7)					
Female	11	9.8	112.4	(56.0-201.0)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	7	6.8	102.4	(41.0-211.0)					
Female	3	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	63	65.5	96.1	(73.9-123.0)					
Female	74	65.7	112.7	(88.5-141.5)					
					Female	13	14.3	91.1	(48.4-155.7)
<u>Pancreas</u>									
					Male	9	9.9	90.6	(41.4-172.1)
					Female	13	12.2	106.7	(56.8-182.5)
<u>Prostate</u>									
					Male	162	132.8	122.0	(103.9-142.3)
<u>Stomach</u>									
					Male	9	9.1	99.2	(45.3-188.3)
					Female	4	6.2	nc	(nc-nc)
<u>Testis</u>									
					Male	4	4.4	nc	(nc-nc)
<u>Thyroid</u>									
					Male	4	3.8	nc	(nc-nc)
					Female	14	12.8	109.6	(59.9-183.9)
<u>Uteri Corpus and Uterus, NOS</u>									
					Female	29	26.9	107.6	(72.1-154.6)
<u>All Sites / Types</u>									
					Male	495	457.3	108.2	(98.9-118.2)
					Female	459	461.1	99.5	(90.6-109.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

228

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	4.0	198.5	(85.5-391.1)	Male	2	2.3	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	20	16.6	120.4	(73.5-185.9)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	2	1.6	nc	(nc-nc)

Female	2	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	9	6.1	147.7	(67.4-280.4)	Female	0	1.8	nc	(nc-nc)
Female	2	6.6	nc	(nc-nc)	Pancreas				
Esophagus					Male	0	1.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	23	15.9	144.4	(91.5-216.7)
Male	1	0.3	nc	(nc-nc)	Stomach				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Kidney & Renal Pelvis					Female	0	0.7	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Testis				
Female	1	1.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Larynx					Thyroid				
Male	1	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Leukemia					Uteri Corpus and Uterus, NOS				
Male	7	1.3	540.5	(216.6-1113.8)	Female	3	3.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	All Sites / Types				
Liver and Intrahepatic Bile Ducts					Male	75	54.3	138.1	(108.6-173.1)
Male	0	0.9	nc	(nc-nc)	Female	58	56.7	102.3	(77.7-132.3)
Female	0	0.3	nc	(nc-nc)					
Lung and Bronchus									
Male	11	7.6	144.9	(72.2-259.3)					
Female	8	8.0	100.3	(43.2-197.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

229

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	2	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	5.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)

Cervix Uteri

Female	0	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	1	2.3	nc	(nc-nc)
------	---	-----	----	---------

Female	2	1.6	nc	(nc-nc)
--------	---	-----	----	---------

Esophagus

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	0	0.1	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Kidney & Renal Pelvis

Male	2	0.7	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.4	nc	(nc-nc)
--------	---	-----	----	---------

Larynx

Male	0	0.3	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	2	0.5	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Liver and Intrahepatic Bile Ducts

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	4	2.7	nc	(nc-nc)
------	---	-----	----	---------

Female	1	2.0	nc	(nc-nc)
--------	---	-----	----	---------

Oral Cavity & Pharynx

Male	1	0.7	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.2	nc	(nc-nc)
--------	---	-----	----	---------

Ovary

Female	1	0.6	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	1	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Prostate

Male	4	6.0	nc	(nc-nc)
------	---	-----	----	---------

Stomach

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.2	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	0	0.3	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.2	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.7	nc	(nc-nc)
--------	---	-----	----	---------

Uteri Corpus and Uterus, NOS

Female	0	1.1	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	21	20.7	101.6	(62.9-155.4)
------	----	------	-------	--------------

Female	10	17.3	57.8	(27.7-106.3)
--------	----	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

230

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.3	96.4	(41.5-190.0)	Male	3	4.6	nc	(nc-nc)
Female	6	3.1	194.0	(70.8-422.3)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.3	nc	(nc-nc)	Male	7	4.3	164.4	(65.9-338.7)
Female	22	31.1	70.8	(44.4-107.2)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.4	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	6	12.5	48.1	(17.6-104.8)	<u>Ovary</u>				
Female	11	12.2	89.9	(44.8-160.9)	Female	3	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	24	32.9	73.0	(46.7-108.6)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.1	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.2	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	6	6.5	92.7	(33.9-201.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.7	nc	(nc-nc)	Male	84	110.7	75.9	(60.5-93.9)
Female	0	0.6	nc	(nc-nc)	Female	96	105.8	90.8	(73.5-110.8)
<u>Lung and Bronchus</u>									
Male	13	15.7	83.1	(44.2-142.0)					
Female	15	14.7	102.0	(57.1-168.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

231

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	16.5	176.1	(117.9-252.9)	Male	13	7.3	177.8	(94.6-304.1)
Female	9	5.8	156.3	(71.3-296.7)	Female	9	5.1	174.8	(79.8-331.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)

Female	1	1.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)	Male	6	7.1	84.4	(30.8-183.7)
Female	64	45.8	139.7	(107.6-178.4)	Female	11	6.8	162.3	(80.9-290.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.6	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Colon / Rectum					Female	0	2.4	nc	(nc-nc)
Male	24	23.4	102.4	(65.6-152.4)	Ovary				
Female	21	22.7	92.5	(57.2-141.3)	Female	5	5.1	97.3	(31.4-227.1)
Esophagus					Pancreas				
Male	3	3.8	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	5	4.9	101.2	(32.6-236.1)
Hodgkin Lymphoma					Prostate				
Male	1	0.6	nc	(nc-nc)	Male	87	59.3	146.6	(117.4-180.9)
Female	0	0.5	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	1	4.0	nc	(nc-nc)
Male	2	5.8	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	5	3.7	135.0	(43.5-315.0)	Testis				
Larynx					Male	1	0.7	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Thyroid				
Female	0	0.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Leukemia					Female	6	3.1	191.7	(70.0-417.3)
Male	10	4.4	228.4	(109.4-420.1)	Uteri Corpus and Uterus, NOS				
Female	6	3.5	169.4	(61.9-368.8)	Female	15	9.9	151.9	(85.0-250.6)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	2	2.8	nc	(nc-nc)	Male	223	197.4	113.0	(98.6-128.8)
Female	2	1.1	nc	(nc-nc)	Female	208	170.6	122.0	(105.9-139.7)
Lung and Bronchus									
Male	19	29.9	63.5	(38.2-99.2)					
Female	29	26.5	109.6	(73.4-157.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

232

Otitis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	2	2.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)

Brain and Other Nervous System

Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Breast

Male	0	0.1	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)

Cervix Uteri

Female	0	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	3	2.9	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)

Esophagus

Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Kidney & Renal Pelvis

Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Larynx

Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Leukemia

Male	1	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Lung and Bronchus

Male	5	3.7	135.0	(43.5-315.0)
Female	3	2.6	nc	(nc-nc)

Multiple Myeloma

Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	1	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

Oral Cavity & Pharynx

Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Ovary

Female	1	0.6	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

Prostate

Male	4	8.0	nc	(nc-nc)
------	---	-----	----	---------

Stomach

Male	1	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)

Testis

Male	0	0.2	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	1	1.2	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	28	26.3	106.5	(70.8-154.0)
Female	13	18.5	70.1	(37.3-119.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				<u>Melanoma of Skin</u>			

Male	19	12.5	152.5	(91.8-238.1)	Male	7	7.5	93.2	(37.3-192.1)
Female	11	4.5	244.0	(121.6-436.5)	Female	5	6.5	77.5	(25.0-180.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	5	2.2	227.2	(73.2-530.2)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	58	50.2	115.6	(87.7-149.4)	Female	4	6.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	5	5.1	98.2	(31.7-229.2)
<u>Colon / Rectum</u>					Female	5	2.4	211.4	(68.1-493.2)
Male	18	18.9	95.1	(56.3-150.3)	<u>Ovary</u>				
Female	12	17.6	68.1	(35.2-119.0)	Female	7	5.3	131.4	(52.6-270.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.3	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	5	3.8	132.8	(42.8-309.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	42	50.0	84.1	(60.6-113.7)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.2	155.9	(50.2-363.8)
Male	6	5.6	107.7	(39.3-234.3)	Female	0	1.9	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.9	119.2	(47.7-245.5)
Male	2	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.3	nc	(nc-nc)	Female	7	10.2	68.5	(27.4-141.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.7	nc	(nc-nc)	Male	174	170.8	101.9	(87.3-118.2)
Female	1	0.9	nc	(nc-nc)	Female	164	164.4	99.7	(85.1-116.2)
<u>Lung and Bronchus</u>									
Male	29	23.5	123.6	(82.8-177.5)					
Female	18	22.0	81.8	(48.4-129.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	14.1	113.4	(64.8-184.2)	Male	6	7.8	76.8	(28.0-167.1)
Female	9	5.7	157.5	(71.9-298.9)	Female	2	6.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
Female	55	53.9	102.1	(76.9-132.8)	Female	3	7.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	8	5.2	154.3	(66.4-304.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	21.0	95.1	(58.1-146.9)	Female	6	5.9	102.0	(37.3-222.1)
Female	27	22.9	117.9	(77.7-171.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	3.5	nc	(nc-nc)	Male	47	53.5	87.8	(64.5-116.8)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.9	119.5	(47.9-246.2)	Female	16	11.0	145.8	(83.3-236.8)
Female	8	4.0	200.2	(86.2-394.5)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Lung and Bronchus</u>				
Male	4	2.3	nc	(nc-nc)	Male	29	26.1	111.1	(74.4-159.5)
Female	0	0.7	nc	(nc-nc)	Female	22	26.5	83.1	(52.1-125.8)
<u>Leukemia</u>									
Male	1	4.5	nc	(nc-nc)					
Female	2	4.0	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	4	2.9	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	11	17.5	63.0	(31.4-112.7)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	8.3	72.1	(26.3-157.0)	Female	2	1.9	nc	(nc-nc)
Female	3	6.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	21.4	46.6	(22.3-85.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	4	2.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.1	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	10	10.4	95.7	(45.8-176.1)	Male	57	72.7	78.4	(59.4-101.6)
Female	4	8.1	nc	(nc-nc)	Female	45	58.2	77.3	(56.4-103.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	63.5	136.9	(109.7-168.9)	Male	28	34.0	82.2	(54.6-118.9)
Female	42	24.3	172.6	(124.4-233.4)	Female	32	28.0	114.4	(78.3-161.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	11.4	114.4	(60.8-195.6)	Male	7	9.5	73.5	(29.4-151.4)
Female	11	9.7	113.1	(56.4-202.3)	Female	10	7.7	129.6	(62.1-238.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.9	nc	(nc-nc)	Male	36	31.5	114.3	(80.1-158.3)
Female	248	230.5	107.6	(94.6-121.8)	Female	36	30.5	118.1	(82.7-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	9.7	113.5	(56.6-203.1)	Male	26	23.1	112.8	(73.6-165.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	109	94.3	115.6	(94.9-139.5)	Female	24	25.1	95.7	(61.3-142.5)
Female	113	95.6	118.2	(97.4-142.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	26	17.9	145.4	(94.9-213.0)
Male	18	16.1	112.1	(66.4-177.1)	Female	23	20.6	111.5	(70.7-167.4)
Female	4	4.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	230	249.2	92.3	(80.7-105.0)
Male	5	4.3	115.5	(37.2-269.5)	<u>Stomach</u>				
Female	2	3.6	nc	(nc-nc)	Male	15	16.0	93.8	(52.5-154.8)
<u>Kidney & Renal Pelvis</u>					Female	13	10.3	126.7	(67.4-216.7)
Male	21	26.2	80.3	(49.7-122.7)	<u>Testis</u>				
Female	14	17.1	82.0	(44.8-137.5)	Male	8	7.1	112.6	(48.5-221.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	14	10.4	134.1	(73.3-225.1)	Male	6	6.9	87.0	(31.8-189.4)
Female	1	3.0	nc	(nc-nc)	Female	23	22.0	104.7	(66.3-157.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	38	19.4	196.3	(138.9-269.4)	Female	49	48.3	101.5	(75.1-134.2)
Female	25	16.5	151.1	(97.8-223.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	893	831.9	107.3	(100.4-114.6)
Male	14	12.6	110.9	(60.6-186.0)	Female	907	800.2	113.4	(106.1-121.0)
Female	7	4.8	145.1	(58.1-299.1)					
<u>Lung and Bronchus</u>									
Male	131	119.0	110.1	(92.0-130.6)					
Female	132	114.8	115.0	(96.2-136.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

237

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	8	6.1	130.8	(56.3-257.8)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	7.5	147.5	(73.5-263.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Male	24	24.5	98.1	(62.8-146.0)
Female	0	0.1	nc	(nc-nc)	Female	18	18.9	95.4	(56.5-150.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.3	nc	(nc-nc)	Male	24	24.5	98.1	(62.8-146.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Female	18	18.9	95.4	(56.5-150.8)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	3.5	nc	(nc-nc)	Male	24	24.5	98.1	(62.8-146.0)
Female	0	2.5	nc	(nc-nc)	Female	18	18.9	95.4	(56.5-150.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

238

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.2	105.8	(59.1-174.4)	Male	15	9.2	162.7	(91.0-268.4)
Female	2	4.9	nc	(nc-nc)	Female	11	7.7	142.4	(71.0-254.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	8.1	135.1	(67.4-241.8)
Female	60	60.4	99.3	(75.8-127.8)	Female	5	6.7	74.1	(23.9-173.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.0	nc	(nc-nc)	Male	11	6.5	168.3	(83.9-301.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	22.1	58.8	(31.3-100.5)	Female	6	6.3	95.2	(34.8-207.1)
Female	13	18.8	69.2	(36.8-118.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	5	4.0	125.7	(40.5-293.2)	Male	61	62.8	97.1	(74.3-124.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.4	nc	(nc-nc)	Male	5	2.7	188.6	(60.8-440.1)
Female	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	7.0	100.7	(40.3-207.4)	Female	12	12.5	95.7	(49.4-167.1)
Female	2	4.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	2.7	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	2	3.4	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Lung and Bronchus</u>				
Male	36	27.7	130.2	(91.2-180.2)	Male	213	206.9	102.9	(89.6-117.7)
Female	37	24.5	151.0	(106.3-208.2)	Female	194	189.9	102.2	(88.3-117.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

239

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.7	64.9	(20.9-151.4)	Male	5	5.3	93.6	(30.2-218.4)
Female	2	2.9	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	35	36.2	96.6	(67.3-134.4)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	1.9	265.2	(85.5-618.9)	Male	3	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	12.2	123.2	(68.9-203.1)	Female	4	3.8	nc	(nc-nc)
Female	5	11.4	44.0	(14.2-102.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	5	2.2	230.0	(74.1-536.8)	Male	0	2.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	0	0.9	nc	(nc-nc)	Male	5	2.0	245.6	(79.1-573.1)
Female	1	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	2	3.9	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.4	nc	(nc-nc)	Female	11	7.2	151.9	(75.7-271.8)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	107	113.3	94.4	(77.4-114.1)
Female	3	2.4	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	2	1.9	nc	(nc-nc)					
Female	4	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	14.9	87.3	(46.4-149.3)					

Female 14 14.1 99.1 (54.1-166.3)

Female 110 113.7 96.8 (79.5-116.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

240
Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>									
Male	0	0.1	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>									
Male	1	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)

Lung and Bronchus

Male	0	1.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)

All Sites / Types

Male	10	11.3	88.4	(42.3-162.6)
Female	2	7.4	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

241

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	4	0.8	nc	(nc-nc)
Female	8	5.7	139.3	(60.0-274.4)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	2.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	6.6	91.0	(33.2-198.1)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)					
Female	1	0.4	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	5	3.1	163.9	(52.8-382.5)	Male	29	21.5	134.6	(90.1-193.4)
Female	1	2.8	nc	(nc-nc)	Female	17	19.9	85.6	(49.9-137.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

242

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	6	5.1	118.7	(43.4-258.5)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	5.8	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>									
Male	0	0.5	nc	(nc-nc)					

Female	2	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Female	0	0.7	nc	(nc-nc)
--------	---	-----	----	---------

Liver and Intrahepatic Bile Ducts

Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	2	1.0	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	2	2.6	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)

All Sites / Types

Male	17	19.8	86.1	(50.1-137.8)
Female	14	15.4	90.6	(49.5-152.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

243

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	71	59.1	120.1	(93.8-151.5)	Male	44	30.6	143.6	(104.4-192.8)
Female	23	23.6	97.4	(61.7-146.1)	Female	38	25.9	146.9	(103.9-201.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	10.2	98.4	(47.1-180.9)	Male	7	8.8	80.0	(32.0-164.8)
Female	7	9.1	77.0	(30.8-158.6)	Female	5	7.5	66.9	(21.5-156.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	37	28.7	128.9	(90.8-177.7)
Female	219	212.0	103.3	(90.1-117.9)	Female	27	29.2	92.4	(60.9-134.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	8.7	126.1	(62.9-225.6)	Male	24	20.2	119.1	(76.3-177.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	115	86.7	132.6	(109.5-159.2)	Female	22	23.3	94.3	(59.1-142.8)
Female	82	94.1	87.1	(69.3-108.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	32	16.4	195.6	(133.8-276.1)
Male	18	14.5	124.5	(73.7-196.7)	Female	21	20.2	103.8	(64.2-158.6)
Female	11	4.6	239.0	(119.1-427.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	194	220.4	88.0	(76.1-101.3)
Male	3	3.9	nc	(nc-nc)	<u>Stomach</u>				
Female	4	3.4	nc	(nc-nc)	Male	7	14.9	47.0	(18.8-96.9)
<u>Kidney & Renal Pelvis</u>					Female	5	10.2	48.8	(15.7-113.9)
Male	19	23.2	81.9	(49.3-127.9)	<u>Testis</u>				
Female	19	16.1	118.2	(71.1-184.6)	Male	11	6.4	171.9	(85.7-307.5)
<u>Larynx</u>									
Male	8	9.3	86.2	(37.1-169.8)					
Female	3	2.7	nc	(nc-nc)					

Leukemia

Male	14	17.8	78.6	(42.9-131.8)
Female	15	16.0	93.6	(52.4-154.5)

Liver and Intrahepatic Bile Ducts

Male	10	11.2	89.1	(42.6-163.8)
Female	8	4.7	170.8	(73.5-336.5)

Lung and Bronchus

Male	109	108.3	100.6	(82.6-121.4)
Female	123	108.8	113.0	(93.9-134.8)

Thyroid

Male	7	6.0	117.3	(47.0-241.8)
Female	9	19.6	46.0	(21.0-87.2)

Uteri Corpus and Uterus, NOS

Female	42	44.1	95.2	(68.6-128.6)
--------	----	------	------	--------------

All Sites / Types

Male	793	752.0	105.5	(98.2-113.1)
Female	780	755.2	103.3	(96.2-110.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

244

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Pancreas				
Esophagus					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	3	3.5	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Stomach				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis					Female	1	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Testis				
Female	1	0.2	nc	(nc-nc)					
Larynx									

Male	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	7	11.3	61.9	(24.8-127.6)
Female	1	1.0	nc	(nc-nc)	Female	9	7.6	117.9	(53.8-223.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

245

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	8.0	113.1	(51.6-214.7)	Male	8	4.6	172.3	(74.2-339.4)
Female	5	2.8	176.7	(57.0-412.4)	Female	5	3.8	131.9	(42.5-307.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.2	118.2	(38.1-275.8)
Female	32	30.2	106.1	(72.6-149.8)	Female	1	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	12.0	124.7	(69.8-205.7)	Female	2	3.2	nc	(nc-nc)
Female	11	10.9	100.9	(50.3-180.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.3	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	32.2	124.2	(88.7-169.1)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>									
Male	7	3.5	199.4	(79.9-410.8)					

Female	5	2.1	235.2	(75.8-549.0)	Female	1	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male	0	1.0	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	Female	5	3.3	151.4	(48.8-353.3)
Female	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female	7	6.2	112.0	(44.9-230.8)
Male	0	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.6	nc	(nc-nc)	Male	124	108.5	114.3	(95.0-136.2)
<u>Lung and Bronchus</u>					Female	113	100.0	113.0	(93.1-135.9)
Male	14	15.1	92.4	(50.5-155.1)					
Female	17	13.8	123.4	(71.8-197.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

246

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	50.8	112.1	(84.9-145.3)	Male	52	30.4	170.8	(127.5-224.0)
Female	17	18.9	90.1	(52.4-144.2)	Female	25	25.4	98.6	(63.8-145.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.8	102.0	(50.8-182.5)	Male	11	7.9	140.0	(69.8-250.6)
Female	16	8.8	182.6	(104.3-296.6)	Female	9	6.0	150.2	(68.5-285.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	37	27.5	134.4	(94.6-185.2)
Female	209	200.4	104.3	(90.6-119.4)	Female	22	24.8	88.7	(55.6-134.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	9.3	96.5	(44.0-183.2)	Male	27	20.6	131.1	(86.4-190.8)
<u>Colon / Rectum</u>					Female	8	9.6	83.2	(35.8-163.9)
Male	96	77.2	124.3	(100.7-151.8)	<u>Ovary</u>				
Female	74	76.1	97.3	(76.4-122.1)	Female	18	21.5	83.8	(49.6-132.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	13.3	82.9	(41.3-148.3)	Male	18	14.6	123.1	(72.9-194.6)
Female	5	3.7	135.9	(43.8-317.1)	Female	16	16.1	99.6	(56.9-161.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.8	nc	(nc-nc)	Male	271	200.1	135.4	(119.8-152.5)
Female	5	3.7	134.6	(43.4-314.2)					

Kidney & Renal Pelvis

Male	29	22.4	129.6	(86.8-186.1)
Female	20	13.9	143.6	(87.7-221.7)

Larynx

Male	11	8.7	127.0	(63.3-227.2)
Female	1	2.4	nc	(nc-nc)

Leukemia

Male	26	17.0	153.3	(100.1-224.7)
Female	21	14.0	150.1	(92.9-229.5)

Liver and Intrahepatic Bile Ducts

Male	6	11.0	54.6	(19.9-118.8)
Female	8	3.9	205.9	(88.7-405.7)

Lung and Bronchus

Male	111	94.3	117.7	(96.8-141.7)
Female	88	88.3	99.6	(79.9-122.7)

Stomach

Male	12	13.1	91.3	(47.1-159.5)
Female	6	8.2	72.9	(26.6-158.7)

Testis

Male	9	8.6	104.5	(47.7-198.3)
------	---	-----	-------	--------------

Thyroid

Male	8	6.8	116.9	(50.4-230.4)
Female	26	22.1	117.4	(76.7-172.0)

Uteri Corpus and Uterus, NOS

Female	39	41.1	94.9	(67.5-129.8)
--------	----	------	------	--------------

All Sites / Types

Male	871	690.5	126.1	(117.9-134.8)
Female	678	668.8	101.4	(93.9-109.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

247

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	10	9.3	107.4	(51.4-197.5)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	3.4	146.5	(47.2-341.9)	<u>Ovary</u>				
Female	3	2.7	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	0	0.2	nc	(nc-nc)	Male	10	9.7	103.1	(49.4-189.7)
Female	0	0.2	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	0.8	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	5	4.2	119.1	(38.4-277.9)	Male	32	32.0	100.1	(68.5-141.4)
Female	7	3.4	207.5	(83.1-427.5)	Female	43	28.1	153.0	(110.7-206.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

248

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.0	164.0	(52.9-382.7)	Male	2	2.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	10	12.4	80.6	(38.6-148.3)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
					Female	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.8	104.5	(33.7-243.8)	Female	0	1.3	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)

Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	13.2	106.3	(58.1-178.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	45	44.1	102.0	(74.4-136.5)
Female	0	0.2	nc	(nc-nc)	Female	25	37.4	66.9	(43.3-98.7)
<u>Lung and Bronchus</u>									
Male	6	5.9	101.6	(37.1-221.2)					
Female	0	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

249

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	5.1	195.6	(93.6-359.7)	Male	4	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	13	16.5	79.0	(42.0-135.1)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	9	7.7	117.0	(53.4-222.1)	<u>Ovary</u>				
Female	9	6.8	132.6	(60.5-251.8)	Female	1	1.8	nc	(nc-nc)

Esophagus

Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Hodgkin Lymphoma

Male	2	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)

Kidney & Renal Pelvis

Male	5	2.2	230.6	(74.3-538.2)
Female	2	1.2	nc	(nc-nc)

Larynx

Male	4	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)

Leukemia

Male	3	1.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	2	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)

Lung and Bronchus

Male	13	9.4	137.8	(73.3-235.6)
Female	17	7.7	221.1	(128.7-354.0)

Pancreas

Male	0	1.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)

Prostate

Male	21	19.8	106.2	(65.7-162.4)
------	----	------	-------	--------------

Stomach

Male	1	1.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)

Testis

Male	0	0.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	3	3.4	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	93	67.6	137.6	(111.0-168.5)
Female	65	56.1	115.8	(89.3-147.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

250

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	103.0	84.5	(67.7-104.2)	Male	69	56.6	121.9	(94.9-154.3)
Female	45	41.6	108.2	(78.9-144.8)	Female	47	49.8	94.4	(69.4-125.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.8	84.9	(48.5-137.9)	Male	18	15.4	116.6	(69.0-184.2)
Female	12	16.9	71.1	(36.7-124.2)	Female	18	13.2	136.9	(81.1-216.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	3.1	nc	(nc-nc)	Male	61	52.1	117.1	(89.5-150.4)
Female	376	389.6	96.5	(87.0-106.8)	Female	51	52.6	96.9	(72.2-127.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	17.3	121.3	(75.0-185.4)	Male	39	36.9	105.7	(75.2-144.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
					Female	16	19.7	81.4	(46.5-132.2)

Male	177	152.6	116.0	(99.5-134.4)					
Female	178	165.3	107.7	(92.5-124.8)	Female	37	42.6	86.8 (61.1-119.6)	
<u>Esophagus</u>					<u>Pancreas</u>				
Male	29	25.7	112.8	(75.5-162.0)	Male	35	28.8	121.6 (84.7-169.1)	
Female	2	8.1	nc	(nc-nc)	Female	30	35.4	84.7 (57.1-120.9)	
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	8.3	108.5	(49.5-206.0)	Male	254	393.3	64.6 (56.9-73.0)	
Female	5	7.1	69.9	(22.5-163.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	27	26.1	103.3 (68.1-150.3)	
Male	35	41.9	83.4	(58.1-116.0)	Female	25	17.9	139.5 (90.2-205.9)	
Female	26	28.9	89.9	(58.7-131.8)	<u>Testis</u>				
<u>Larynx</u>					Male	11	15.1	72.7 (36.2-130.1)	
Male	22	16.6	132.4	(82.9-200.4)	<u>Thyroid</u>				
Female	7	5.0	140.6	(56.3-289.7)	Male	10	11.9	84.0 (40.2-154.5)	
<u>Leukemia</u>					Female	48	40.4	118.9 (87.6-157.6)	
Male	27	31.9	84.5	(55.7-123.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	18	28.7	62.8	(37.2-99.2)	Female	76	80.9	94.0 (74.0-117.6)	
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	37	20.3	182.6	(128.6-251.7)	Male	1272	1344.2	94.6 (89.5-100.0)	
Female	13	8.3	156.3	(83.2-267.3)	Female	1390	1369.7	101.5 (96.2-107.0)	
<u>Lung and Bronchus</u>									
Male	205	190.4	107.7	(93.4-123.4)					
Female	240	193.3	124.1	(108.9-140.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

251

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	33.9	100.3	(69.4-140.2)	Male	12	19.1	62.7	(32.3-109.5)
Female	14	12.5	112.1	(61.2-188.0)	Female	9	16.2	55.4	(25.3-105.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.6	nc	(nc-nc)	Male	7	5.2	135.9	(54.4-279.9)
Female	8	5.6	143.1	(61.6-282.0)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	20	17.5	114.0	(69.6-176.0)
Female	129	128.8	100.1	(83.6-119.0)	Female	14	16.2	86.5	(47.2-145.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	7	12.9	54.1	(21.7-111.5)

Female	4	5.9	nc	(nc-nc)	Female	9	6.2	144.2	(65.8-273.8)
Colon / Rectum					Ovary				
Male	45	50.9	88.5	(64.5-118.4)	Female	21	13.8	151.8	(93.9-232.0)
Female	60	49.2	121.8	(93.0-156.8)	Pancreas				
Esophagus					Male	5	9.6	52.0	(16.7-121.2)
Male	5	8.7	57.5	(18.5-134.3)	Female	14	10.5	132.8	(72.5-222.8)
Female	2	2.4	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	139	133.0	104.5	(87.9-123.4)
Male	3	2.7	nc	(nc-nc)	Stomach				
Female	5	2.4	211.9	(68.3-494.5)	Male	11	8.6	127.4	(63.5-227.9)
Kidney & Renal Pelvis					Female	6	5.3	114.0	(41.6-248.2)
Male	15	14.4	104.1	(58.2-171.7)	Testis				
Female	7	9.2	76.5	(30.6-157.6)	Male	3	4.7	nc	(nc-nc)
Larynx					Thyroid				
Male	4	5.7	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	16	13.9	114.9	(65.6-186.6)
Leukemia					Uteri Corpus and Uterus, NOS				
Male	8	10.8	73.8	(31.8-145.4)	Female	23	26.6	86.4	(54.7-129.6)
Female	9	8.9	100.6	(45.9-191.0)	All Sites / Types				
Liver and Intrahepatic Bile Ducts					Male	431	451.6	95.4	(86.6-104.9)
Male	5	7.0	71.2	(22.9-166.1)	Female	479	434.0	110.4	(100.7-120.7)
Female	2	2.5	nc	(nc-nc)					
Lung and Bronchus									
Male	67	63.3	105.8	(82.0-134.4)					
Female	86	59.4	144.7	(115.7-178.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

252

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	14	12.8	109.7	(59.9-184.1)	Male	5	7.3	68.0	(21.9-158.8)
Female	2	4.8	nc	(nc-nc)	Female	5	6.3	79.6	(25.7-185.9)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	2.6	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	10	6.7	149.4	(71.5-274.7)
Female	47	50.3	93.4	(68.7-124.3)	Female	1	6.2	nc	(nc-nc)

Cervix Uteri

Female	3	2.3	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	24	19.3	124.4	(79.7-185.1)
Female	15	18.8	79.7	(44.6-131.4)

Esophagus

Male	5	3.3	150.3	(48.4-350.8)
Female	0	0.9	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)

Kidney & Renal Pelvis

Male	6	5.6	107.8	(39.4-234.7)
Female	2	3.5	nc	(nc-nc)

Larynx

Male	2	2.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Leukemia

Male	4	4.1	nc	(nc-nc)
Female	6	3.4	174.7	(63.8-380.2)

Liver and Intrahepatic Bile Ducts

Male	5	2.7	184.4	(59.4-430.3)
Female	0	1.0	nc	(nc-nc)

Lung and Bronchus

Male	26	24.0	108.3	(70.7-158.7)
Female	29	22.9	126.9	(85.0-182.3)

Oral Cavity & Pharynx

Male	4	5.1	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)

Ovary

Female	3	5.4	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	7	3.7	191.1	(76.5-393.7)
Female	7	4.0	174.1	(69.7-358.7)

Prostate

Male	63	51.2	123.1	(94.6-157.5)
------	----	------	-------	--------------

Stomach

Male	2	3.3	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)

Testis

Male	3	1.8	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	1.6	nc	(nc-nc)
Female	7	5.4	129.6	(51.9-267.1)

Uteri Corpus and Uterus, NOS

Female	7	10.5	67.0	(26.8-138.0)
--------	---	------	------	--------------

All Sites / Types

Male	201	172.5	116.5	(101.0-133.8)
Female	149	167.8	88.8	(75.1-104.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

253

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	26.1	107.4	(71.4-155.3)	Male	22	14.7	149.9	(93.9-227.0)
Female	13	9.9	131.4	(69.9-224.8)	Female	20	12.4	161.8	(98.8-249.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.1	157.0	(67.6-309.3)	Male	3	4.0	nc	(nc-nc)
Female	6	4.3	139.3	(50.9-303.2)	Female	1	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.8	nc	(nc-nc)	Male	11	13.5	81.8	(40.8-146.3)
Female	138	100.8	136.8	(115.0-161.7)	Female	13	12.7	102.8	(54.7-175.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.5	nc	(nc-nc)	Male	3	9.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	4.9	123.1	(45.0-268.0)
Male	34	39.1	87.0	(60.2-121.6)	<u>Ovary</u>				
Female	42	39.0	107.8	(77.7-145.7)	Female	13	10.8	120.3	(64.0-205.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.7	74.8	(24.1-174.5)	Male	8	7.4	108.2	(46.6-213.2)
Female	3	1.9	nc	(nc-nc)	Female	6	8.4	71.8	(26.2-156.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	121	102.1	118.6	(98.4-141.7)
Female	0	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.6	90.5	(33.0-197.0)
Male	14	11.1	125.7	(68.7-210.9)	Female	3	4.2	nc	(nc-nc)
Female	7	7.2	97.3	(39.0-200.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.4	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	15	10.3	145.5	(81.4-240.0)
Male	2	8.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.0	85.5	(31.2-186.2)	Female	15	20.8	72.2	(40.4-119.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.4	nc	(nc-nc)	Male	337	346.6	97.2	(87.1-108.2)
Female	1	2.0	nc	(nc-nc)	Female	380	339.5	111.9	(101.0-123.8)
<u>Lung and Bronchus</u>									
Male	39	48.9	79.8	(56.7-109.1)					
Female	39	46.9	83.2	(59.1-113.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

254

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	10.0	160.6	(91.7-260.8)	Male	14	6.3	221.6	(121.1-371.9)
Female	4	3.3	nc	(nc-nc)	Female	10	5.0	198.4	(95.0-364.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)

Female	1	1.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	6	5.6	106.8	(39.0-232.5)
Female	39	40.6	96.1	(68.3-131.4)	Female	3	4.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	1.9	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Colon / Rectum					Female	1	1.8	nc	(nc-nc)
Male	14	15.6	90.0	(49.2-151.1)	Ovary				
Female	9	13.0	69.2	(31.6-131.3)	Female	2	4.2	nc	(nc-nc)
Esophagus					Pancreas				
Male	2	2.8	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.9	nc	(nc-nc)	Male	53	43.1	123.0	(92.2-160.9)
Female	0	0.7	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	3	2.6	nc	(nc-nc)
Male	10	4.8	208.3	(99.7-383.0)	Female	1	1.4	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Testis				
Larynx					Male	1	1.6	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	Thyroid				
Female	0	0.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Leukemia					Female	8	4.7	170.9	(73.6-336.7)
Male	6	3.4	177.1	(64.7-385.4)	Uteri Corpus and Uterus, NOS				
Female	6	2.5	240.7	(87.9-523.8)	Female	3	8.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	3	2.4	nc	(nc-nc)	Male	156	142.9	109.2	(92.7-127.7)
Female	1	0.7	nc	(nc-nc)	Female	114	127.6	89.4	(73.7-107.4)
Lung and Bronchus									
Male	14	19.3	72.6	(39.7-121.8)					
Female	13	16.5	78.8	(41.9-134.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

255

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	79	56.4	140.1	(110.9-174.6)	Male	20	30.3	66.1	(40.4-102.1)
Female	30	21.5	139.7	(94.3-199.5)	Female	28	25.3	110.5	(73.4-159.8)

Brain and Other Nervous System

Male	9	10.2	88.5	(40.4-168.1)
Female	10	8.7	114.5	(54.8-210.6)

Breast

Male	3	1.7	nc	(nc-nc)
Female	190	199.8	95.1	(82.1-109.6)

Cervix Uteri

Female	13	8.8	147.2	(78.3-251.7)
--------	----	-----	-------	--------------

Colon / Rectum

Male	91	83.2	109.4	(88.1-134.3)
Female	102	84.9	120.2	(98.0-145.9)

Esophagus

Male	10	14.0	71.5	(34.2-131.6)
Female	4	4.2	nc	(nc-nc)

Hodgkin Lymphoma

Male	5	4.3	117.6	(37.9-274.4)
Female	10	3.6	278.1	(133.2-511.5)

Kidney & Renal Pelvis

Male	30	22.7	132.1	(89.1-188.6)
Female	17	14.9	113.8	(66.2-182.2)

Larynx

Male	9	9.0	100.0	(45.6-189.8)
Female	6	2.6	232.1	(84.8-505.3)

Leukemia

Male	22	17.5	126.1	(79.0-190.9)
Female	16	14.9	107.5	(61.4-174.6)

Liver and Intrahepatic Bile Ducts

Male	13	10.9	119.8	(63.7-204.8)
Female	4	4.3	nc	(nc-nc)

Lung and Bronchus

Male	144	104.5	137.9	(116.3-162.3)
Female	126	100.1	125.8	(104.8-149.8)

Multiple Myeloma

Male	10	8.4	119.0	(57.0-218.8)
Female	9	6.8	132.5	(60.5-251.6)

Non-Hodgkin Lymphoma

Male	29	28.1	103.3	(69.2-148.4)
Female	32	27.1	118.1	(80.8-166.8)

Oral Cavity & Pharynx

Male	18	19.6	91.6	(54.3-144.8)
Female	9	10.1	89.3	(40.7-169.5)

Ovary

Female	19	21.9	86.8	(52.2-135.5)
--------	----	------	------	--------------

Pancreas

Male	16	15.7	101.9	(58.2-165.4)
Female	24	18.2	131.6	(84.3-195.8)

Prostate

Male	175	213.9	81.8	(70.1-94.9)
------	-----	-------	------	-------------

Stomach

Male	19	14.3	133.2	(80.2-208.0)
Female	18	9.2	195.7	(115.9-309.3)

Testis

Male	10	7.6	132.1	(63.3-243.0)
------	----	-----	-------	--------------

Thyroid

Male	9	6.2	144.4	(65.9-274.1)
Female	22	20.4	107.9	(67.6-163.4)

Uteri Corpus and Uterus, NOS

Female	35	41.6	84.1	(58.6-117.0)
--------	----	------	------	--------------

All Sites / Types

Male	779	730.0	106.7	(99.3-114.5)
Female	773	704.1	109.8	(102.2-117.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				

Male	0	2.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	10	8.2	122.3	(58.5-224.9)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.4	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	12	9.7	123.3	(63.6-215.3)
Male	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	30	31.0	96.8	(65.3-138.3)
Male	2	0.5	nc	(nc-nc)	Female	30	26.5	113.3	(76.4-161.8)
Female	1	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	4.4	114.4	(36.9-267.1)					
Female	2	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.3	139.2	(50.8-302.9)	Male	4	2.8	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.5	201.4	(64.9-470.0)
Female	14	17.7	79.1	(43.2-132.7)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.8	88.7	(32.4-193.2)	Female	4	1.8	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	19	18.5	102.5	(61.7-160.1)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.5	nc	(nc-nc)	Female	8	3.6	223.4	(96.2-440.3)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	60	62.2	96.4	(73.6-124.1)
Male	0	1.1	nc	(nc-nc)	Female	58	54.8	105.8	(80.3-136.8)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	8.3	84.3	(33.8-173.6)					
Female	8	6.9	116.2	(50.0-228.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	17.4	138.0	(88.4-205.4)	Male	12	10.0	120.0	(61.9-209.6)
Female	6	7.0	85.7	(31.3-186.5)	Female	7	9.0	77.6	(31.1-159.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	10	9.1	109.4	(52.4-201.2)
Female	68	71.5	95.1	(73.8-120.5)	Female	7	9.0	77.4	(31.0-159.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.3	nc	(nc-nc)	Male	10	6.7	149.8	(71.7-275.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	26.1	126.3	(86.9-177.4)	Female	5	7.7	65.1	(21.0-151.8)
Female	28	27.3	102.6	(68.2-148.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	4.5	nc	(nc-nc)	Male	49	68.9	71.2	(52.6-94.1)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	7.5	nc	(nc-nc)	Female	19	14.9	127.6	(76.8-199.3)
Female	6	5.1	117.1	(42.7-254.8)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	2.9	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	6	5.7	105.2	(38.4-228.9)	Male	45	32.8	137.1	(100.0-183.5)
Female	4	5.0	nc	(nc-nc)	Female	42	33.6	125.0	(90.1-169.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.4	88.0	(42.1-161.8)	Male	6	5.9	102.4	(37.4-223.0)
Female	2	4.6	nc	(nc-nc)	Female	5	5.0	99.1	(31.9-231.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
Female	45	43.1	104.4	(76.1-139.7)	Female	4	5.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	5	4.0	124.8	(40.2-291.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	16.8	65.6	(32.7-117.4)	Female	5	4.7	106.7	(34.4-249.0)
Female	14	18.5	75.7	(41.4-127.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.2	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	Female	5	4.0	126.3	(40.7-294.7)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	41	42.3	97.0	(69.6-131.6)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.0	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.3	nc	(nc-nc)	Female	8	9.0	88.9	(38.3-175.2)
Female	2	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	123	143.9	85.5	(71.0-102.0)
Male	3	2.2	nc	(nc-nc)	Female	144	149.9	96.1	(81.0-113.1)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	20.6	68.0	(37.2-114.2)					
Female	26	21.4	121.7	(79.5-178.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

260

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	1.1	nc	(nc-nc)	Male	9	7.8	115.8	(52.8-219.8)
Female	2	0.9	nc	(nc-nc)	Female	5	6.3	79.9	(25.7-186.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

261

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.5	134.2	(49.0-292.2)	Male	3	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	14	20.0	70.1	(38.3-117.7)	Female	4	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	6.9	115.4	(49.7-227.5)	Female	4	2.1	nc	(nc-nc)
Female	7	7.0	100.5	(40.3-207.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.3	nc	(nc-nc)
Male	4	1.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	18.3	98.6	(58.4-155.8)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.8	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	Female	0	4.0	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	67	63.3	105.8	(82.0-134.3)
Male	1	1.1	nc	(nc-nc)	Female	55	64.3	85.5	(64.4-111.3)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	8.4	71.1	(26.0-154.7)					
Female	6	8.1	74.2	(27.1-161.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

262

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	4.9	122.1	(44.6-265.9)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	14	16.7	83.8	(45.8-140.6)
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	2.3	nc	(nc-nc)					

Female	4	1.7	nc	(nc-nc)	Female	13	13.9	93.8	(49.9-160.4)
--------	---	-----	----	---------	--------	----	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;